Lenalidomide
Brand name: Revlimid
Rank #7 of 500 drugs by total cost
$2.15B
Total Cost
130,834
Total Claims
$2.15B
Total Cost
3,935
Prescribers
$16K
Cost per Claim
11,562
Beneficiaries
130,893
30-Day Fills
$548K
Avg Cost/Provider
33
Avg Claims/Provider
About Lenalidomide
Lenalidomide (sold as Revlimid) was prescribed 130,834 times by 3,935 Medicare Part D providers in 2023, costing the program $2.15B. At $16K per claim, this is a high-cost medication.
💰 This drug alone accounts for 0.8% of all Medicare Part D drug spending.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 4 | Dulaglutide (Trulicity) | $2.99B | 2,175,100 |
| 5 | Rivaroxaban (Xarelto) | $2.45B | 2,628,123 |
| 6 | Adalimumab (Humira(Cf) Pen) | $2.17B | 240,925 |
| 7 | Lenalidomide (Revlimid) | $2.15B | 130,834 |
| 8 | Insulin Glargine,hum.Rec.Anlog (Lantus Solostar) | $1.94B | 3,118,259 |
| 9 | Fluticasone/Umeclidin/Vilanter (Trelegy Ellipta) | $1.81B | 2,046,216 |
| 10 | Dapagliflozin Propanediol (Farxiga) | $1.65B | 1,666,200 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology